Objective: To investigate the interventional effect of Dan-fang capsule on liver fibrosis in rats. Methods: Sixty one-week aged male healthy SD rats [weight (180±20) g] were randomly divided into normal control group (group A), hepatic fibrosis model group (group B), Fu-Fang-Bie-Jia-Ruan-Gan tablet group (group C), Dan-fang capsule groups at high, middle and low dose group (group D, E, F, respectively). Except for the normal control group, hepatic fibrosis was induced in other groups by intraperitoneal injection of porcine serum.Simultaneously, rats in Dan-fang capsule groups were administered by gavage with Dan-fang capsule at doses of 4.32, 2.16, 0.54 g/kg, respectively.Rats in Fu-Fang-Bie-Jia-Ruan-Gan tablet group were orally administered by gavage with Fu-Fang-Bie-Jia-Ruan-Gan tablet (0.54 g/kg) every day and the normal control group received saline alone.All rats were killed at the end of the 12th week. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and PⅢnp clia (PⅢNP) were measured in the groups.Pathology changes of hepatic tissue were evaluated by hematoxylin-eosin (HE) and Masson staining.The proteinic expressions of alpha-smooth muscle actin (α-SMA), collagen-Ⅰ (COL-Ⅰ) and collagen-Ⅲ (COL-Ⅲ) were observed with the method of immunohistochemistry.Analysis of variance was applied when data were compared among groups. Results: Compared with those in the group A, the levels of ALT, AST and PⅢNP in serum and the expressions of α-SMA, COL-Ⅰ and COL-Ⅲ in liver tissues were significantly higher in group B [(68.3±3.4) vs (51.5±6.3) U/L, (205±52) vs (135±24) U/L, (3.1±1.4) vs (1.6±0.6) μg/L and 0.35±0.02 vs 0.13±0.02, 0.37±0.02 vs 0.13±0.02, 0.43±0.13 vs 0.13±0.01, t=17.020, 71.053, 1.552, 0.214, 0.241, 0.292, all P<0.01], and the degree of liver fibrosis significantly increased in group B than that in group A. Compared with those in group B, the levels of ALT, AST, PⅢNP and the expressions of α-SMA, COL-Ⅰ, COL-Ⅲ were all significantly lower in group D, E and F (t=-58.232--0.104, all P<0.01). The degree of liver fibrosis significantly reduced in group D, E and F than that in group B (Z=3.82, 3.76, 3.90, all P<0.05). Conclusion: Dan-fang capsule has certain preventive effect on liver fibrosis that caused by porcine serum in rats.
目的： 探讨丹防胶囊对猪血清致大鼠肝纤维化的干预作用。 方法： 健康雄性1周龄SD大鼠[体重(180±20) g]60只经适应性喂养后，随机分为6组，即正常组(A组)、模型组(B组)、复方鳖甲软肝片组(C组)、丹防胶囊高剂量组(D组)、丹防胶囊中剂量组(E组)、丹防胶囊低剂量组(F组)，每组10只。除A组外，其余各组均采用腹腔注射无菌猪血清复制大鼠肝纤维化模型。造模的同时，D、E、F组分别给予丹防胶囊4.32、2.16、0.54 g/kg灌胃，C组给予复方鳖甲软肝片(0.54 g/kg)灌胃，每日1次，共12周。12周末股动脉放血处死大鼠，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、Ⅲ型前胶原N端肽(PⅢNP)；行肝组织病理学检查；检测肝脏组织α平滑肌肌动蛋白(α－SMA)、Ⅰ型胶原(COL－Ⅰ)、Ⅲ型胶原(COL－Ⅲ)的表达。多组比较采用单因素方差分析。 结果： B组血清中ALT、AST、PⅢNP水平和肝组织中α－SMA、COL－Ⅰ、COL－Ⅲ蛋白表达均显著高于A组，差异有统计学意义[(68.3±3.4)比(51.5±6.3) U/L、(205±52)比(135±24) U/L、(3.1±1.4)比(1.6±0.6) μg/L和0.35±0.02比0.13±0.02、0.37±0.02比0.13±0.02、0.43±0.13比0.13±0.01，t＝17.020、71.053、1.552、0.214、0.241、0.292，均P<0.01]。病理检查显示B组肝纤维化程度高于A组；丹防胶囊各剂量组血清ALT、AST、PⅢNP水平和肝组织中α－SMA、COL－Ⅰ、COL－Ⅲ蛋白表达均明显低于B组，差异均有统计学意义(t＝－58.232～－0.104，均P<0.01)。而丹防胶囊各剂量组肝纤维化程度亦明显低于B组，差异有统计学意义(Z＝3.821、3.761、3.904，P<0.05)。 结论： 丹防胶囊对猪血清致大鼠肝纤维化有一定的预防保护作用。.
Keywords: Alpha-smooth muscle actin; Collagen Ⅰ; Collagen Ⅲ; Dan-Fang capsule; Liver cirrhosis.